Protagonist Therapeutics Inc (PTGX)

$85.60 +2.84 (3.43%)
Market Cap 5.17B
Revenue (ttm) 434.43M
Net Income (ttm) 275.19M
EPS (ttm) N/A
PE Ratio 134.02
Forward PE 77.05
Profit Margin 63.35%
Debt to Equity Ratio 0.00
Volume 334,828
Avg Vol 797,940
Day's Range N/A - N/A
Shares Out 62.52M
Stochastic %K 53%
Beta 2.26
Analysts Strong Sell
Price Target $99.33

Company Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 474 0170
Address:
7707 Gateway Boulevard, Suite 140, Newark, United States
BillionerOfKing
BillionerOfKing Feb. 22 at 6:24 PM
$PTGX Current Stock Price: $82.84 Contracts to trade: $85.0 PTGX Mar 20 2026 Call Entry: $2.60 Exit: $3.26 ROI: 25% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 20 at 11:58 AM
$PTGX https://www.biotechtv.com/post/protagonist-therapeutics-february-19-2026
0 · Reply
NoEmotionzTrade
NoEmotionzTrade Feb. 19 at 5:52 AM
$AGAE tightening right where momentum traders watch. Above .50, this becomes a breakout story. .75 is the natural next zone, and the 200MA around 1.2 is the full technical reversion target. In a float this small, expansion can be aggressive & fast $PRAX $PTGX $RCKT $ASTS
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 11 at 6:39 PM
$PTGX Share Price: $82.54 Contract Selected: Jul 17, 2026 $85 Calls Buy Zone: $6.46 – $7.98 Target Zone: $11.85 – $14.48 Potential Upside: 73% ROI Time to Expiration: 155 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 3 at 5:03 PM
$PTGX RSI: 59.71, MACD: -0.6534 Vol: 1.75, MA20: 82.56, MA50: 86.10 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 2 at 4:36 PM
$PTGX Share Price: $82.58 Contract Selected: Jul 17, 2026 $85 Calls Buy Zone: $7.14 – $8.82 Target Zone: $13.54 – $16.55 Potential Upside: 79% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 30 at 4:08 PM
$PTGX Share Price: $79.65 Contract Selected: Jul 17, 2026 $80 Calls Buy Zone: $5.95 – $7.35 Target Zone: $9.55 – $11.67 Potential Upside: 52% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Quantumup
Quantumup Jan. 27 at 12:39 PM
JPMorgan reiterated $PTGX Overweight; $93 and said, With shares pulling back from all-time highs in mid-Dec (-14% since Dec 12th), we wanted to re-evaluate the key levers in the story and discuss the set-up for the remainder of the year. $JNJ $ABVX $ALMS LLY ABBV PFE $TAK JPMorgan went on to say: https://x.com/Quantumup1/status/2016126900440043740?s=20
0 · Reply
zmanx
zmanx Jan. 23 at 9:13 AM
$PTGX another strong BO candidate
0 · Reply
biochirp
biochirp Jan. 22 at 7:46 PM
$PTGX cheap right now
0 · Reply
Latest News on PTGX
Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 5:35 PM EST - 5 weeks ago

Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

Jan 7, 2026, 7:30 AM EST - 6 weeks ago

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Jan 5, 2026, 7:00 AM EST - 7 weeks ago

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

TAK

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

Dec 6, 2025, 9:30 AM EST - 2 months ago

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

TAK

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 4:05 PM EST - 3 months ago

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

Nov 3, 2025, 4:05 PM EST - 3 months ago

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make

Oct 12, 2025, 9:00 AM EDT - 4 months ago

Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make

JNJ

RTW Investments' Rod Wong: Expect more deals in biotech space

Oct 10, 2025, 1:21 PM EDT - 4 months ago

RTW Investments' Rod Wong: Expect more deals in biotech space

JNJ XBI

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

Oct 10, 2025, 1:06 PM EDT - 4 months ago

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

JNJ

Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports

Oct 10, 2025, 11:25 AM EDT - 4 months ago

Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports

JNJ

Johnson & Johnson in Talks to Buy Protagonist Therapeutics

Oct 10, 2025, 11:13 AM EDT - 4 months ago

Johnson & Johnson in Talks to Buy Protagonist Therapeutics

JNJ

Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 11, 2025, 1:08 AM EDT - 5 months ago

Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 1:39 PM EDT - 6 months ago

Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

Aug 26, 2025, 4:05 PM EDT - 6 months ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Jun 26, 2025, 7:05 AM EDT - 8 months ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case

Jun 20, 2025, 5:27 PM EDT - 8 months ago

Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Jun 1, 2025, 8:00 AM EDT - 9 months ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

TAK

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

May 21, 2025, 7:05 AM EDT - 9 months ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 4:05 PM EDT - 10 months ago

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

Apr 23, 2025, 10:35 AM EDT - 10 months ago

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

Protagonist Therapeutics Reports Granting of Inducement Award

Apr 16, 2025, 4:05 PM EDT - 11 months ago

Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Mar 18, 2025, 7:00 AM EDT - 1 year ago

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Mar 11, 2025, 4:00 PM EDT - 1 year ago

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Overlooked Stock: PTGX

Mar 10, 2025, 4:57 PM EDT - 1 year ago

Overlooked Stock: PTGX

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Mar 10, 2025, 10:04 AM EDT - 1 year ago

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Mar 3, 2025, 6:45 AM EST - 1 year ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

TAK

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 21, 2025, 7:00 AM EST - 1 year ago

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Jan 13, 2025, 5:55 AM EST - 1 year ago

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Protagonist Therapeutics Reports Granting of Inducement Awards

Jan 6, 2025, 4:05 PM EST - 1 year ago

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 19, 2024, 4:05 PM EST - 1 year ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

Nov 22, 2024, 7:30 AM EST - 1 year ago

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Nov 19, 2024, 7:30 AM EST - 1 year ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 4:05 PM EST - 1 year ago

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

Nov 5, 2024, 4:05 PM EST - 1 year ago

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines

Sep 10, 2024, 1:17 PM EDT - 1 year ago

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

Jul 31, 2024, 9:15 AM EDT - 1 year ago

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

May 31, 2024, 7:30 AM EDT - 1 year ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

May 14, 2024, 4:05 PM EDT - 1 year ago

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

May 7, 2024, 4:10 PM EDT - 1 year ago

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 4:05 PM EDT - 1 year ago

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

Mar 26, 2024, 7:00 AM EDT - 2 years ago

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

Mar 18, 2024, 7:00 AM EDT - 2 years ago

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Mar 6, 2024, 4:05 PM EST - 2 years ago

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 27, 2024, 4:05 PM EST - 2 years ago

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

Feb 21, 2024, 5:00 PM EST - 2 years ago

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

Feb 7, 2024, 5:00 PM EST - 2 years ago

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

BillionerOfKing
BillionerOfKing Feb. 22 at 6:24 PM
$PTGX Current Stock Price: $82.84 Contracts to trade: $85.0 PTGX Mar 20 2026 Call Entry: $2.60 Exit: $3.26 ROI: 25% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 20 at 11:58 AM
$PTGX https://www.biotechtv.com/post/protagonist-therapeutics-february-19-2026
0 · Reply
NoEmotionzTrade
NoEmotionzTrade Feb. 19 at 5:52 AM
$AGAE tightening right where momentum traders watch. Above .50, this becomes a breakout story. .75 is the natural next zone, and the 200MA around 1.2 is the full technical reversion target. In a float this small, expansion can be aggressive & fast $PRAX $PTGX $RCKT $ASTS
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 11 at 6:39 PM
$PTGX Share Price: $82.54 Contract Selected: Jul 17, 2026 $85 Calls Buy Zone: $6.46 – $7.98 Target Zone: $11.85 – $14.48 Potential Upside: 73% ROI Time to Expiration: 155 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 3 at 5:03 PM
$PTGX RSI: 59.71, MACD: -0.6534 Vol: 1.75, MA20: 82.56, MA50: 86.10 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 2 at 4:36 PM
$PTGX Share Price: $82.58 Contract Selected: Jul 17, 2026 $85 Calls Buy Zone: $7.14 – $8.82 Target Zone: $13.54 – $16.55 Potential Upside: 79% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 30 at 4:08 PM
$PTGX Share Price: $79.65 Contract Selected: Jul 17, 2026 $80 Calls Buy Zone: $5.95 – $7.35 Target Zone: $9.55 – $11.67 Potential Upside: 52% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Quantumup
Quantumup Jan. 27 at 12:39 PM
JPMorgan reiterated $PTGX Overweight; $93 and said, With shares pulling back from all-time highs in mid-Dec (-14% since Dec 12th), we wanted to re-evaluate the key levers in the story and discuss the set-up for the remainder of the year. $JNJ $ABVX $ALMS LLY ABBV PFE $TAK JPMorgan went on to say: https://x.com/Quantumup1/status/2016126900440043740?s=20
0 · Reply
zmanx
zmanx Jan. 23 at 9:13 AM
$PTGX another strong BO candidate
0 · Reply
biochirp
biochirp Jan. 22 at 7:46 PM
$PTGX cheap right now
0 · Reply
Quantumup
Quantumup Jan. 21 at 6:54 PM
Chardan🏁 $ALMS Buy/$37 $BMY $TAK ABBV $JNJ - $PTGX NVS LLY Here's what Chardan said in its initiation report: https://x.com/Quantumup1/status/2014048081944182966?s=20
0 · Reply
JackDarwin
JackDarwin Jan. 21 at 10:54 AM
$PTGX Bullish Piercing Candlestick Pattern Formed
0 · Reply
1986iamwallstreet
1986iamwallstreet Jan. 16 at 3:17 PM
$JNJ is either buying $ABVX or $PTGX 🚀🚀🚀
0 · Reply
biochirp
biochirp Jan. 14 at 4:21 PM
$PTGX gotta think J&J will make a move soon Maybe couldn’t find agreement for JPM announcement
0 · Reply
StockConsultant
StockConsultant Jan. 14 at 1:57 PM
$PTGX Protagonist Therapeutics stock watch, attempting to move higher off the 80.3 support area
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 14 at 12:39 PM
$PTGX RSI: 23.76, MACD: -1.5961 Vol: 4.01, MA20: 86.09, MA50: 85.68 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 13 at 4:23 PM
$PTGX icotrokinra is now ICOTIDE!
0 · Reply
Quantumup
Quantumup Jan. 13 at 12:01 PM
Guggenheim reiterated Best Idea $ABVX at Buy/$175 after hosting an investor dinner with Abivax's management yesterday. $LLY ABBV PFE $PTGX - JNJ Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2011044955871920247?s=20
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 13 at 4:27 AM
$PTGX JPM Healthcare Conference Day/Time: Tuesday, January 13 at 8:15 AM PST Webcast: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317262-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=true
0 · Reply
AlucardPendragon
AlucardPendragon Jan. 12 at 5:59 PM
$PTGX looks like i was wrong. Closed my position at a $1K loss
0 · Reply
AlucardPendragon
AlucardPendragon Jan. 9 at 8:29 PM
$PTGX I'm thinking they get bought out at$110 by JnJ on Monday
1 · Reply
Quantumup
Quantumup Jan. 8 at 11:45 AM
BTIG⬆️ $ABVX's PT to $150 from $120 and reiterated at a Buy after ABVX announced an updated 2026 outlook for their clinical pipeline. LLY PFE ABBV $PTGX - $JNJ Here's what BTIG had to say: https://x.com/Quantumup1/status/2009229128763953344?s=20
0 · Reply